Xiao-Ming Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xiao-Ming Yin has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Wen-Xing Ding
Pathology University of Pittsburgh School of Medicine, Pittsburgh, PA
11 shared publicationsHong-Min Ni
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
9 shared publicationsWentao Gao
Pathology University of Pittsburgh School of Medicine, Pittsburgh, PA
7 shared publicationsXiaoyun Chen
Pathology University of Pittsburgh School of Medicine, Pittsburgh, PA
6 shared publicationsDonna B. Stolz
4 shared publicationsAndrea A. Gambotto
3 shared publications
Latest Publications
- 1 January 2011
- Published by Springer Nature
- p. 390-393
Bid
- Open Access
- 23 June 2010
- Published by Wolters Kluwer Health in Hepatology
- Vol. 52 (1) , 338-348
Bid Agonist Regulates Murine Hepatocyte Proliferation by Controlling Endoplasmic Reticulum Calcium Homeostasis
BH3-interacting domain death agonist (Bid), a BH3-only B cell lymphoma 2 family molecule, is generally known for its importance in activating the mitochondrial apoptosis pathway after death receptor engagement, particularly in hepatocytes. However, Bid also promotes hepatocyte proliferation during liver regeneration and carcinogenesis. This study was designed to examine the hypothesis that Bid regulates endoplasmic reticulum calcium concentration ([Ca2+]ER) homeostasis to affect hepatocyte proliferation. We found that serum-stimulated hepatocyte proliferation was dependent on calcium, and the depletion of calcium with thapsigargin or ethylene glycol tetraacetic acid (EGTA) inhibited the proliferation. Subcellular fractionation showed that a portion of Bid was inserted into the endoplasmic reticulum (ER)–enriched membranes, and single-cell calcium imaging indicated that Bid was important for maintaining the [Ca2+]ER level. Bid-deficient hepatocytes manifested delayed and reduced serum-stimulated proliferation, which was corrected by ionomycin or reconstitution of Bid, particularly an ER-targeted Bid. Finally, B cell lymphoma 2–associated X protein (Bax) could also be found in the ER-enriched membranes, and Bax deficiency caused the same proliferation defect. However, Bid/Bax double deletion in hepatocytes did not further augment the defect, which suggested that Bid and Bax worked by the same regulatory mechanism in [Ca2+]ER control. Conclusion: Bid regulates hepatocyte proliferation by positively affecting [Ca2+]ER homeostasis, and this could be important for liver regeneration and carcinogenesis. (Hepatology 2010)
- 23 June 2010
- Published by Wolters Kluwer Health in Hepatology
- Vol. 52 (1) , 338-348
Open AccessBid Agonist Regulates Murine Hepatocyte Proliferation by Controlling Endoplasmic Reticulum Calcium Homeostasis
BH3-interacting domain death agonist (Bid), a BH3-only B cell lymphoma 2 family molecule, is generally known for its importance in activating the mitochondrial apoptosis pathway after death receptor engagement, particularly in hepatocytes. However, Bid also promotes hepatocyte proliferation during liver regeneration and carcinogenesis. This study was designed to examine the hypothesis that Bid regulates endoplasmic reticulum calcium concentration ([Ca2+]ER) homeostasis to affect hepatocyte proliferation. We found that serum-stimulated hepatocyte proliferation was dependent on calcium, and the depletion of calcium with thapsigargin or ethylene glycol tetraacetic acid (EGTA) inhibited the proliferation. Subcellular fractionation showed that a portion of Bid was inserted into the endoplasmic reticulum (ER)–enriched membranes, and single-cell calcium imaging indicated that Bid was important for maintaining the [Ca2+]ER level. Bid-deficient hepatocytes manifested delayed and reduced serum-stimulated proliferation, which was corrected by ionomycin or reconstitution of Bid, particularly an ER-targeted Bid. Finally, B cell lymphoma 2–associated X protein (Bax) could also be found in the ER-enriched membranes, and Bax deficiency caused the same proliferation defect. However, Bid/Bax double deletion in hepatocytes did not further augment the defect, which suggested that Bid and Bax worked by the same regulatory mechanism in [Ca2+]ER control. Conclusion: Bid regulates hepatocyte proliferation by positively affecting [Ca2+]ER homeostasis, and this could be important for liver regeneration and carcinogenesis. (Hepatology 2010)
- Open Access
- 1 January 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (2) , 1371-1383
Biochemical Isolation and Characterization of the Tubulovesicular LC3-positive Autophagosomal Compartment
- 1 January 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (2) , 1371-1383
Open AccessBiochemical Isolation and Characterization of the Tubulovesicular LC3-positive Autophagosomal Compartment
- 21 December 2009
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 58 (7) , 3957-3964
Delphinidin Induces Necrosis in Hepatocellular Carcinoma Cells in the Presence of 3-Methyladenine, an Autophagy Inhibitor
The present study was performed to determine whether anthocyanins could trigger different modes of cell death in different cancers. It was found that whereas cyanidin-3-rutinoside and delphinidin could induce apoptosis in leukemia cells, they caused growth retardation in hepatocellular carcinoma cells (HCC), which was accompanied with a significant cellular vacuolization. The latter was likely caused by macroautophagy and was completely suppressed by 3-methyladenine, an inhibitor of class III phosphoinositide 3-kinase that is important for autophagy activation, and by bafilomycin A1, which blocks lysosomal degradation. Delphinidin induced significant lipidation of LC3, an indication of macroautophagy, which was also suppressed by 3-methyladenine. Macroautophagy was required for the survival of delphinidin-treated HCC cells as inhibition with 3-methyladenine led to massive necrosis without caspase activation. Thus, anthocyanins could induce different modes of cell death for different cancers. Furthermore, anthocyanins could be used in combination with a macroautophagy inhibitor for treating cancers such as HCC.
- 21 December 2009
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 58 (7) , 3957-3964
Delphinidin Induces Necrosis in Hepatocellular Carcinoma Cells in the Presence of 3-Methyladenine, an Autophagy Inhibitor
The present study was performed to determine whether anthocyanins could trigger different modes of cell death in different cancers. It was found that whereas cyanidin-3-rutinoside and delphinidin could induce apoptosis in leukemia cells, they caused growth retardation in hepatocellular carcinoma cells (HCC), which was accompanied with a significant cellular vacuolization. The latter was likely caused by macroautophagy and was completely suppressed by 3-methyladenine, an inhibitor of class III phosphoinositide 3-kinase that is important for autophagy activation, and by bafilomycin A1, which blocks lysosomal degradation. Delphinidin induced significant lipidation of LC3, an indication of macroautophagy, which was also suppressed by 3-methyladenine. Macroautophagy was required for the survival of delphinidin-treated HCC cells as inhibition with 3-methyladenine led to massive necrosis without caspase activation. Thus, anthocyanins could induce different modes of cell death for different cancers. Furthermore, anthocyanins could be used in combination with a macroautophagy inhibitor for treating cancers such as HCC.
- Open Access
- 1 July 2009
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (7) , 2036-2045
Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy
The proteasome and the autophagy systems are two evolutionarily conserved mechanisms for degrading intracellular materials. They are functionally coupled and suppression of the proteasome promotes autophagy. Although suppression of the proteasome leads to cell death, suppression of autophagy can be either prodeath or prosurvival. To understand the underlining mechanism of this dichotomy and its potential clinical implications, we treated various transformed and nontransformed human cells with proteasome inhibitors. We found that whether autophagy served a prosurvival role in this scenario was contingent on the cellular oncogenic status. Thus, autophagy suppression enhanced apoptosis induced by proteasome inhibitors in transformed cells, but not in nontransformed cells. Oncogenic transformation enhanced the ability of cells to initiate autophagy in response to stress, reflecting a stronger dependence of transformed cells on autophagy for survival. Indeed, a combined use of bortezomib, the only Food and Drug Administration–approved proteasome inhibitor for clinical use, and chloroquine, which inhibits autophagy by disturbing lysosomal functions, suppressed tumor growth more significantly than either agent alone in a xenograft model. These findings indicate that suppression of both intracellular degradation systems could constitute a novel strategy for enhanced cancer control in a tumor-specific way. [Mol Cancer Ther 2009;8(7):2036–45]
- 1 July 2009
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (7) , 2036-2045
Open AccessOncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy
The proteasome and the autophagy systems are two evolutionarily conserved mechanisms for degrading intracellular materials. They are functionally coupled and suppression of the proteasome promotes autophagy. Although suppression of the proteasome leads to cell death, suppression of autophagy can be either prodeath or prosurvival. To understand the underlining mechanism of this dichotomy and its potential clinical implications, we treated various transformed and nontransformed human cells with proteasome inhibitors. We found that whether autophagy served a prosurvival role in this scenario was contingent on the cellular oncogenic status. Thus, autophagy suppression enhanced apoptosis induced by proteasome inhibitors in transformed cells, but not in nontransformed cells. Oncogenic transformation enhanced the ability of cells to initiate autophagy in response to stress, reflecting a stronger dependence of transformed cells on autophagy for survival. Indeed, a combined use of bortezomib, the only Food and Drug Administration–approved proteasome inhibitor for clinical use, and chloroquine, which inhibits autophagy by disturbing lysosomal functions, suppressed tumor growth more significantly than either agent alone in a xenograft model. These findings indicate that suppression of both intracellular degradation systems could constitute a novel strategy for enhanced cancer control in a tumor-specific way. [Mol Cancer Ther 2009;8(7):2036–45]
- 20 April 2009
- Published by Springer Nature
- p. 691-711
Analysis of Apoptosis: Basic Principles and Protocols
- 20 April 2009
- Published by Springer Nature
- p. 691-711
Analysis of Apoptosis: Basic Principles and Protocols
- 20 April 2009
- Published by Springer Nature
- p. 25-61
The Bcl-2 Family Proteins
- Open Access
- 1 February 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (7) , 4373-4382
Genetic Delineation of the Pathways Mediated by Bid and JNK in Tumor Necrosis Factor-α-induced Liver Injury in Adult and Embryonic Mice
- 1 February 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (7) , 4373-4382
Open AccessGenetic Delineation of the Pathways Mediated by Bid and JNK in Tumor Necrosis Factor-α-induced Liver Injury in Adult and Embryonic Mice
- 1 October 2008
- Published by Elsevier in The American Journal of Pathology
- Vol. 173 (4) , 962-972
Differential Roles of JNK in ConA/GalN and ConA-Induced Liver Injury in Mice
- 1 October 2008
- Published by Elsevier in The American Journal of Pathology
- Vol. 173 (4) , 962-972
Differential Roles of JNK in ConA/GalN and ConA-Induced Liver Injury in Mice